Valiant Capital Management’s Editas Medicine EDIT Stock Holding History

Valiant Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-379,800	Closed	-$11.2M	–	24
2019 Q4	$11.2M	Hold	379,800	–	–	1.31%	15
2019 Q3	$8.64M	Hold	379,800	–	–	0.47%	16
2019 Q2	$9.4M	Hold	379,800	–	–	0.76%	13
2019 Q1	$9.29M	Hold	379,800	–	–	0.83%	14
2018 Q4	$8.64M	Hold	379,800	–	–	0.81%	15
2018 Q3	$12.1M	Buy	+379,800	New	+$12.3M	1.07%	14

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Valiant Capital Management's EDIT Position: Q1 2020 in Review

Valiant Capital Management sold out of Editas Medicine (EDIT) in Q1 2020, closing a stake of 379,800 shares — an estimated $11.2M sold.

Valiant Capital Management first reported a position in EDIT in Q3 2018 and held it in 6 quarters. The position peaked at $12.1M in Q3 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q1 2020.

Valiant Capital Management reported no remaining Editas Medicine position as of Q1 2020 after selling out during the quarter.
Valiant Capital Management sold 379,800 Editas Medicine shares in Q1 2020, an estimated $11.2M.
Valiant Capital Management first reported a position in Editas Medicine in Q3 2018 and held it in 6 quarters.
Valiant Capital Management's Editas Medicine position peaked at $12.1M in Q3 2018.
199 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2020.

Based on Valiant Capital Management's 13F filing for Q1 2020, filed 13 May 2020.